Results of a five-year clinical trial confirming the long-term durability of Rezūm™ Water Vapor Therapy for treatment of benign prostatic hyperplasia (BPH) was published in the Journal of Urology. The supplement, available online now, includes standard and late-breaking abstracts for the American Urological Association (AUA) Annual Meeting.
The abstract notes that the study found the Rezūm System provided significant, sustained improvement of lower urinary tract symptoms (LUTS) and quality of life for patients suffering from BPH out to five years post-procedure. More detailed results will be released later this year.
Why: BPH is a common condition that affects roughly half of all men by the age of 60, and up to 90 percent of men by the age of 85.(1) BPH can cause symptoms like frequent or urgent urination, a weak or interrupted urine stream, and the need to get up several times a night to urinate. Medications to treat BPH may not work for many or may have undesirable side effects.(2) And some minimally invasive procedures may only treat BPH symptoms, not the underlying condition.
At the end of the five-year trial, the medication and surgical retreatment rates were:
- 4.4 percent of the Rezūm System patients required surgical retreatment through 5 years
- 11.1 percent of the Rezūm System patients required medications through five years
The study also solidified the therapy’s International Prostate Symptom Score (IPSS), Qmax (peak urinary flow rate) and quality of life improvements at 48 percent, 49 percent and 49 percent respectively, all significantly improved from baseline.